Tocilizumab in Severe and Critical COVID-19 Pneumonia: Streamlining the Mixed Signals.
作者信息
Santiaguel Joel M, Zamora Mithi Kalayaan S
机构信息
Division of Pulmonary Medicine, Department of Medicine, Philippine General Hospital, University of the Philippines Manila.
出版信息
Acta Med Philipp. 2024 Apr 15;58(6):3-4. doi: 10.47895/amp.v58i6.10156. eCollection 2024.
Abstract
摘要
相似文献
1
Tocilizumab in Severe and Critical COVID-19 Pneumonia: Streamlining the Mixed Signals.托珠单抗治疗重症和危重症 COVID-19 肺炎：梳理混杂信号
Acta Med Philipp. 2024 Apr 15;58(6):3-4. doi: 10.47895/amp.v58i6.10156. eCollection 2024.
2
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.托珠单抗联合瑞德西韦治疗重症 COVID-19 肺炎住院患者：一项随机临床试验。
Intensive Care Med. 2021 Nov;47(11):1258-1270. doi: 10.1007/s00134-021-06507-x. Epub 2021 Oct 5.
3
Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.皮质类固醇和托珠单抗可降低重症 COVID-19 肺炎患者的院内死亡率：一项西班牙医院的回顾性研究
Infect Dis (Lond). 2021 Apr;53(4):291-302. doi: 10.1080/23744235.2021.1884286. Epub 2021 Feb 23.
4
Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.托珠单抗治疗的重症新型冠状病毒肺炎患者的继发感染风险
Am J Ther. 2022;29(3):e275-e278. doi: 10.1097/MJT.0000000000001487. Epub 2022 Mar 4.
5
Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.托珠单抗辅助治疗中重度 COVID-19 肺炎患者：一项观察性研究。
J Assoc Physicians India. 2022 Jan;70(1):11-12.
6
Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.静脉注射甲基强的松龙联合或不联合托珠单抗治疗需要吸氧支持的重症 COVID-19 肺炎患者：一项前瞻性比较。
J Infect Public Health. 2021 Aug;14(8):985-989. doi: 10.1016/j.jiph.2021.06.003. Epub 2021 Jun 10.
7
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.托珠单抗在住院的中重度 COVID-19 肺炎患者中联合或不联合皮质类固醇的实际应用：一项回顾性队列研究。
PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.
8
Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.托珠单抗4或8mg/kg用于中度至重度新型冠状病毒肺炎住院患者的安全性和有效性：一项随机临床试验
Open Forum Infect Dis. 2021 Dec 4;9(1):ofab608. doi: 10.1093/ofid/ofab608. eCollection 2022 Jan.
9
Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single-center, Double-blind, Placebo-controlled, Phase 3 Trial.托珠单抗静脉注射对比标准治疗方案用于治疗重度及危重型新型冠状病毒肺炎相关肺炎：一项单中心、双盲、安慰剂对照的3期试验
Acta Med Philipp. 2024 Apr 15;58(6):7-13. doi: 10.47895/amp.vi0.6175. eCollection 2024.
10
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
本文引用的文献
1
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.托珠单抗对COVID-19患者的临床结局有影响吗？一项随机对照试验的荟萃分析。
J Pharm Policy Pract. 2023 Nov 20;16(1):151. doi: 10.1186/s40545-023-00662-w.
2
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review.冠状病毒病（COVID-19）的病理生理学和临床管理：小型综述。
Front Immunol. 2023 Aug 14;14:1116131. doi: 10.3389/fimmu.2023.1116131. eCollection 2023.
3
Parameters to Predict the Outcome of Severe and Critical COVID-19 Patients when Admitted to the Hospital.预测重型和危重型新型冠状病毒肺炎患者入院时预后的参数
J Clin Med. 2023 Feb 7;12(4):1323. doi: 10.3390/jcm12041323.
4
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.托珠单抗、沙利鲁单抗与 COVID-19 住院患者 28 天全因死亡率的关联：一项网状荟萃分析。
PLoS One. 2022 Jul 8;17(7):e0270668. doi: 10.1371/journal.pone.0270668. eCollection 2022.
5
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 住院患者的疗效：系统评价和荟萃分析。
Respirology. 2021 Nov;26(11):1027-1040. doi: 10.1111/resp.14152. Epub 2021 Oct 3.
6
Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.托珠单抗治疗重症 COVID-19 患者：社区医院病例系列研究。
J Pharm Pract. 2022 Aug;35(4):587-592. doi: 10.1177/08971900211002353. Epub 2021 Mar 19.
7
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
8
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment.新型冠状病毒肺炎（COVID-19）：对其发病机制、临床表现和治疗的最新认识。
Postgrad Med J. 2021 May;97(1147):312-320. doi: 10.1136/postgradmedj-2020-138577. Epub 2020 Sep 25.
9
COVID-19 pathophysiology: A review.新型冠状病毒肺炎的病理生理学：综述。
Clin Immunol. 2020 Jun;215:108427. doi: 10.1016/j.clim.2020.108427. Epub 2020 Apr 20.
10
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.理解 SARS-CoV-2 介导的炎症反应：从机制到潜在的治疗工具。
Virol Sin. 2020 Jun;35(3):266-271. doi: 10.1007/s12250-020-00207-4. Epub 2020 Mar 3.
Zotero 插件